SecBot SecBot
144 ·Filed Jul 6, 2026

PBYI

PUMA BIOTECHNOLOGY, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001959173-26-005126
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a standard sell-to-cover for tax obligations on restricted stock vesting — not a bearish signal. The CEO remains a director and officer with a large continuing stake. No follow-through action beyond the scheduled sale is expected.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
PBYI ▲ +24.75% at T+60d
NEUTRAL call +24.75% · α vs SPY +22.54% · entry $7.96 → $9.93
Entry = T+0 close
Jul 6, 2026
via day close
T+1d
+2.14%
call +2.14% · α +2.44%
$8.13
settled 4mo ago
T+5d
+4.02%
call +4.02% · α +3.47%
$8.28
settled 4mo ago
T+20d
-3.39%
call -3.39% · α -4.72%
$7.69
settled 3mo ago
T+60d
+24.75%
call +24.75% · α +22.54%
$9.93
settled 28d ago

Price Chart

Loading chart...

Executive Summary

CEO Alan Auerbach files Form 144 to sell 44,058 shares, currently worth approximately $364K, to cover a tax withholding obligation from the vesting of restricted stock. The sale is a routine 'sell-to-cover' transaction, not a discretionary portfolio exit, and represents a small fraction of Auerbach's total position given the $420M market cap.

Key Facts

  • Filer is CEO/President Alan H. Auerbach — the highest-ranking insider.
  • Proposed sale date: July 6, 2026; 44,058 shares at ~$364K estimated value.
  • Sale explicitly attributed to tax withholding obligation from RSU/settlement of vested equity award.
  • Only ~0.09% of market cap (~$420M) — de minimis.
  • Recent insider activity shows 5 sales totaling $573K in last 30 days, consistent with ongoing tax/RSU settlements.

Financial Impact

Proceeds ~$364K, ~0.09% of market cap.

insider_holdings

Risk Factors

  • If subsequent Form 4 filings show material open-market discretionary selling beyond tax-related transactions, it would signal a change.
  • Potential unobserved insider selling if more than one insider also files similar tax-related 144s in close succession.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-005126
Document: 0001959173-26-005126-index.html0001959173-26-005126
Document: 0001959173-26-005126.txt0001959173-26-005126
7 reports for PBYI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for PBYI — sortable, filterable
TypeNow
Oct 6, 2026
20d ago
SC 13D/A
NEUTRAL ★ 3/10
$9.81awaiting T+20—$10.92 (+11.31%)
Sep 16, 2026
5w ago
Insider Cluster
BEARISH ★ 4/10
$9.52 $10.52▼ −10.50%▼ −9.30%$10.92 (−14.71%)
Jul 8, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.90 $8.12▲ +2.78%▲ +0.54%$10.92 (+38.23%)
Jul 6, 2026
16w ago
144
NEUTRAL ★ 2/10
$7.96 $7.69▼ −3.39%▼ −4.72%$10.92 (+37.19%)
Jun 15, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.17 $8.28▲ +15.48%▲ +15.28%$10.92 (+52.30%)
Jun 12, 2026
19w ago
144
NEUTRAL ★ 2/10
$7.33 $8.00▲ +9.14%▲ +7.36%$10.92 (+48.98%)
Feb 26, 2026
34w ago
8-K
MIXED ★ 6/10
$5.70 $6.08▲ +6.67%▲ +14.22%$10.92 (+91.58%)
Showing 7 of 7

US Market Status

Market Closed — Opens Wed (17h 24m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 6, 2026